Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Alessandra Trojani, Alessandro Beghini, Luca Emanuele Emanuele Bossi, Marta Rachele Stefanucci, Cassandra Palumbo, Antonino Greco, Annamaria Frustaci, Barbara Di Camillo, Marco Montillo, Roberto Cairoli

Blood (2023) 142 (Supplement 1): 3406.

https://doi.org/10.1182/blood-2023-180580

Published: 2023

Journal Articles

Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods

Luca Emanuele Emanuele Bossi, Cassandra Palumbo, Alessandra Trojani, Agostina Melluso, Barbara Di Camillo, Alessandro Beghini, Marco Montillo, Roberto Cairoli

Blood (2023) 142 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2023-185825

Published: 2023

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance ( IgM MGUS ) Compared to Healthy Subjects

Alessandra Trojani, Barbara Di Camillo, Luca Emanuele Bossi, Antonino Greco, Livia Leuzzi, Alessandra Tedeschi, Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Agostina Melluso, Alessia Panzeri, Marco Montillo, Alessandro Beghini, Roberto Cairoli

Blood (2021) 138 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2021-147712

Published: 2021

Journal Articles

Cell Surface Proteins of B Cells and Plasmacells Are Differently Expressed in Waldenström's Macroglobulinemia (WM) Patients Vs. Subjects with Monoclonal Gammopathy of Uncertain Significance (IgMMGUS) Vs. Healthy Donors

Alessandra Trojani, PhD, Barbara Di Camillo, Luca Emanuele Bossi, Alessandra Tedeschi, MD, Annamaria Frustaci, Alessandro Beghini, Marco Montillo, Roberto Cairoli, MD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-134569

Published: 2020

Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Blood (2019) 134 (Supplement_1): 5034.

https://doi.org/10.1182/blood-2019-125595

Published: 2019

Journal Articles

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Alessandra Trojani, Alessandra Tedeschi, MD, Annamaria Maria Frustaci, Marina Deodato, Luca Emanuele Bossi, Barbara Di Camillo, Marco Montillo, MD, Enrica Morra, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 5036.

https://doi.org/10.1182/blood-2019-125577

Published: 2019

Journal Articles

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Blood (2018) 132 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2018-99-112188

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Blood (2018) 132 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2018-99-113273

Published: 2018

Journal Articles

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2889.

https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889

Published: 2017

Journal Articles

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Blood (2017) 130 (Supplement 1): 4973.

https://doi.org/10.1182/blood.V130.Suppl_1.4973.4973

Published: 2017

Journal Articles

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Blood (2016) 128 (22): 3080.

https://doi.org/10.1182/blood.V128.22.3080.3080

Published: 2016

Journal Articles

Transcriptome Analysis Identified Significant Differences in Gene Expression Variability Between WM and IgM-MGUS BM B Cell Clones

Alessandra Trojani, Milena Lodola, Alessandra Tedeschi, Antonino Greco, Barbara Di Camillo, Tiziana Sanavia, Anna Maria Frustaci, Maddalena Mazzucchelli, Chiara Villa, Daniela Boselli, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2016) 128 (22): 5089.

https://doi.org/10.1182/blood.V128.22.5089.5089

Published: 2016

Journal Articles

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Alessandra Trojani, PhD, Ester Pungolino, MD, Milena Lodola, Barbara Di Camillo, Mariella D'Adda, MD, Alessandra Perego, MD, Mauro Turrini, MD, Chiara Elena, MD, Alessandra Iurlo, MD PhD, Cristina Buccelli, Simona Malato, MD, Francesco Spina, MD, Maria Luisa Latargia, Francesco Lanza, Sergio Pauli, MD, Michela Anghilieri, MD, Maria Cristina Carraro, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 3645.

https://doi.org/10.1182/blood.V126.23.3645.3645

Published: 2015

Journal Articles

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Blood (2015) 126 (23): 1486.

https://doi.org/10.1182/blood.V126.23.1486.1486

Published: 2015

Journal Articles

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Blood (2015) 126 (23): 1597.

https://doi.org/10.1182/blood.V126.23.1597.1597

Published: 2015

Journal Articles

Transcriptome-Wide Analysis of Bone Marrow CD19+ Cells As Well As Bone Marrow B Cell Clones of Waldenström's Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, MD, Milena Lodola, Barbara Di Camillo, Anna Maria Frustaci, Enrica Morra

Blood (2014) 124 (21): 5176.

https://doi.org/10.1182/blood.V124.21.5176.5176

Published: 2014

Journal Articles

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Alessandra Trojani, Milena Lodola, Barbara Di Camillo, Giuseppe Rossi, MD, Adele Capucci, Alessandra Perego, Enrico Maria Pogliani, MD, Ester Orlandi, MD, Alessandra Iurlo, MD PhD, Simona Malato, Paolo Corradini, MD, Roberto Cairoli, Marco Bregni, Salvatore Artale, Enrica Morra, Ester Pungolino, MD

Blood (2014) 124 (21): 5177.

https://doi.org/10.1182/blood.V124.21.5177.5177

Published: 2014

Journal Articles

Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)

Blood (2014) 124 (21): 5178.

https://doi.org/10.1182/blood.V124.21.5178.5178

Published: 2014

NARROW

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance ( IgM MGUS ) Compared to Healthy Subjects

Cell Surface Proteins of B Cells and Plasmacells Are Differently Expressed in Waldenström's Macroglobulinemia (WM) Patients Vs. Subjects with Monoclonal Gammopathy of Uncertain Significance (IgMMGUS) Vs. Healthy Donors

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Transcriptome Analysis Identified Significant Differences in Gene Expression Variability Between WM and IgM-MGUS BM B Cell Clones

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Transcriptome-Wide Analysis of Bone Marrow CD19+ Cells As Well As Bone Marrow B Cell Clones of Waldenström's Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only